Wei-ren M. Liu

Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.

Journal: The New England journal of medicine

Published: March 04, 2026

Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.

Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.

Journal: Experimental hematology & oncology

Published: July 23, 2025

Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.

Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.

Journal: Cancer letters

Published: July 16, 2025

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Journal: Science advances

Published: May 02, 2025

Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.

Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.

Journal: Hepatology (Baltimore, Md.)

Published: April 07, 2025

Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation.

Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation.

Journal: International journal of biological macromolecules

Published: April 22, 2024

Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.

Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: March 05, 2024

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells.

Journal: Signal transduction and targeted therapy

Published: February 07, 2024

Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.

Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.

Journal: Journal of translational medicine

Published: June 14, 2023

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy.

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy.

Journal: Science advances

Published: April 28, 2023

Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.

Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.

Journal: Hepatology international

Published: April 26, 2023

Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma.

Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma.

Journal: International immunopharmacology

Published: February 10, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026